Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361079 | 0.91 | CYP2C19 (0.39) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL7433180 | 0.85 | CYP2C19 (0.36) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL769942 | 0.81 | DGAT1 (0.39) | ALDH1A1TP53CYP3A4MAPK1SMN1; SMN2 | |
| SCHEMBL7445820 | 0.79 | POLB (0.35) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL21645431 | 0.78 | CYP2C19 (0.35) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL7214329 | 0.78 | CYP2C19 (0.35) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL5879371 | 0.77 | ZDHHC20 (0.40) | CYP2C19POLBLMNAMAPT | |
| SCHEMBL770755 | 0.77 | CYP2C19 (0.39) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| SCHEMBL27412775 | 0.77 | MAPT (0.41) | CYP2C19POLBTDP1ALDH1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL16982684 | 0.76 | MAPT (0.40) | CYP2C19POLBTDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | CYP2C19 5/4885POLB 2157/4885TDP1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.